Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Constrictive Bronchiolitis Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Wound Healing Endpoint and Recurrence

NCT02577120
View directory record Official record
Conditions
Chronic Wound, Burn Wound, Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, Chronic, Wound
Interventions
Epiceram Skin Barrier Function, Vaseline Petroleum Jelly
Device · Biological
Lead sponsor
Sashwati Roy
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jul 22, 2026, 9:04 AM EDT
Not listed Phase 2 Interventional

Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy

NCT00800943
View directory record Official record
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
Alemtuzumab (Campath-1H)
Biological
Lead sponsor
Chronic Lymphocytic Leukemia Research Consortium
Network
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
3
States / cities
La Jolla, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2008 · Synced Jul 22, 2026, 9:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Pain Perception Between Males and Females Following Laparoscopic Cholecystectomy

NCT00575276
View directory record Official record
Conditions
Cholecystitis, Acute, Cholecystitis, Chronic
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Jul 22, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits

NCT06288217
View directory record Official record
Conditions
Upper Extremity Paresis, Stroke, Chronic
Interventions
NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation), Upper Limb Rehabilitation, Sham Stimulation
Device · Other
Lead sponsor
NeuraStasis, Inc
Industry
Eligibility
30 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 9:04 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
INCA034176, Placebo, Corticosteroids
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 9:04 AM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 9:04 AM EDT
Recruiting Phase 2 Interventional

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

NCT05922761
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
Interventions
Belumosudil, Fluticasone, Azithromycin, Prednisone, Montelukast
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Results available

Combining Medications to Enhance Depression Outcomes

NCT00590863
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI + placebo, Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Harbor City, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Jul 22, 2026, 9:04 AM EDT
Terminated Not applicable Interventional

Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds

NCT02071979
View directory record Official record
Conditions
Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers
Interventions
Autologous PRP Gel, Autologous PRP Injections, Autologous PRP Gel plus PRP Injections, Standard Wound Care
Device · Procedure
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
6
States / cities
Bakersfield, California • Idaho Falls, Idaho • Englewood, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Jul 22, 2026, 9:04 AM EDT
Terminated Phase 2 Interventional

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

NCT06271616
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Interventions
Echocardiography Test, Ibrutinib
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 9:04 AM EDT
Recruiting No phase listed Observational

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

NCT07434869
View directory record Official record
Conditions
Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans, Extracorporeal Photopheresis
Interventions
Not listed
Lead sponsor
Brian Keller
Other
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 9:04 AM EDT
Terminated Phase 2 Interventional Results available

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

NCT01226420
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Alefacept
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Jul 22, 2026, 9:04 AM EDT
Suspended Phase 1 Interventional

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT05993611
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
Interventions
Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Echocardiography, Electronic Health Record Review, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Tafasitamab, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jul 22, 2026, 9:04 AM EDT
Recruiting No phase listed Observational

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

NCT05919511
View directory record Official record
Conditions
cGVHD
Interventions
Non-Interventional
Other
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 22, 2026, 9:04 AM EDT
Completed No phase listed Observational

Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.

NCT01174277
View directory record Official record
Conditions
Blood Stem Cell Transplant Failure, Graft Versus Host Disease
Interventions
Collection of blood sample
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
7 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Jul 22, 2026, 9:04 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Axatilimab, Ruxolitinib, Corticosteroids
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 9:04 AM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

NCT07395232
View directory record Official record
Conditions
Atopic Keratoconjunctivitis
Interventions
DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Jacksonville, Florida • Miami, Florida • Morrow, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 22, 2026, 9:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Can Immune Parameters Predict Acute and Chronic Rejection in Lung Recipients?

NCT00340951
View directory record Official record
Conditions
Lung Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Durham, North Carolina • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease

NCT03483675
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Immunosuppressive Therapy, Survey Administration
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 22, 2026, 9:04 AM EDT
Terminated Phase 3 Interventional

CIS001 Extension Study of Cyclosporine Inhalation Solution

NCT00938236
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Jul 22, 2026, 9:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

NCT06434363
View directory record Official record
Conditions
Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Interventions
Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 9:04 AM EDT
Completed No phase listed Observational

Surgery Checklist and Process Improvement Surrounding Endoscopic Sinus Surgery

NCT01499719
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Checklist introduction / Pause
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Jul 22, 2026, 9:04 AM EDT
Completed Phase 1Phase 2 Interventional

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

NCT00078234
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Oblimersen-rituximab-fludarabine
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Buffalo, New York • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Jul 22, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT02130557
View directory record Official record
Conditions
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
Interventions
Bosutinib, Imatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
65
States / cities
Anaheim, California • Atlanta, Georgia • Honolulu, Hawaii + 40 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Jul 22, 2026, 9:04 AM EDT